middle.news
How PYC Therapeutics Cleared Safety Hurdles to Advance PYC-001 in Blinding Eye Disease
9:42am on Thursday 9th of October, 2025 AEDT
•
Biotechnology
Read Story
How PYC Therapeutics Cleared Safety Hurdles to Advance PYC-001 in Blinding Eye Disease
9:42am on Thursday 9th of October, 2025 AEDT
Key Points
Safety Review Committee finds no safety concerns in Phase 1 Single Ascending Dose study
PYC-001 targets the genetic cause of blinding eye disease ADOA
Multiple Ascending Dose Phase 1/2 trial planned to start in Q4 2025
Trial progression contingent on regulatory and ethics approvals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE